FDA Raises Serious Doubts Over Replimune’s RP1 Melanoma Therapy Ahead of Key Panel

FDA briefing docs criticize Replimune’s RP1 trial data, raising doubts over effectiveness and sending shares down ahead of Thursday’s panel.